FDA · FDA approves Hibsago, a hepatitis B drug that lets some patients stop treatment
In two trials, 24% of patients on Hibsago qualified to stop their hepatitis B medicine. None of the patients on placebo did.
Latest
FDA · Newsletter
The week in health tech, in five minutes.
The health tech news that matters, every morning. What changed, the number, and the link. Free, weekly, by email.